Wynden Pharmaceuticals Inc. plans to raise $23 million to test and eventually commercialize a drug targeted at the cardiology and oncology markets. The Alpharetta-based specialty pharmaceutical company, which employs about six, has changed the formulation of an existing nutritional supplement.
